Audentes Therapeutics. Letter to the XLMTM Patient Community. June23, 2020.
2.
MackDL, PoulardK, GoddardMA, et al.Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. Mol. Ther., 2017; 25: 839–854.
3.
PhillipsA, BelleA, GuoJ, et al.Nonhuman Primate Safety and Potency of an AAV Vector for XLMTM Produced by Transient Transfection at 500 L. Presentation at: American Society of Gene & Cell Therapy Annual Meeting; May 10–13, 2017; Washington, DC.
4.
MendellJR, Al-ZaidyS, ShellR, et al.Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med., 2017; 377: 1713–1722.
5.
FlotteTR. Revisiting the “New” Inflammatory Toxicities of Adeno-Associated Virus Vectors. Hum. Gene Ther., 2020; 31: 398–399.
6.
HindererC, KatzN, BuzaEL, et al.Severe Toxicity in Nonhuman Primates and Piglets following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum. Gene Ther., 2018; 29: 285–298.
7.
SomanathanS, CalcedoR, WilsonJM. Adeno-virus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial. Mol. Ther., 2020; 28: 784–793.
